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ABSTRACT
CYP3A5 is a drug metabolism enzyme that is polymorphically expressed in
normal tissues and expressed in high amounts in some cancers, including pancreatic
ductal adenocarcinoma (PDAC). There have been several published studies regarding
CYP3A5 regulators, but there is still much to be discovered concerning CYP3A5
regulation in cancer. To further understand the regulation of CYP3A5, a high-throughput
screen was performed in the AsPC-1 PDAC cell line. This screen employed small
interfering RNA (siRNA) targeting transcription factors and chromatin-associated
proteins. We identified siRNA that decreased CYP3A5 mRNA and protein levels in
AsPC-1 cells and probed into the potential mechanisms. Taken together, this study
brought to light a previously undescribed regulator of CYP3A5 expression.
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CHAPTER 1.

INTRODUCTION

Drug Metabolism and the Cytochrome P450s
Drugs and environmental chemicals (xenobiotics) as well as endogenous
compounds (endobiotics) must go through biotransformation and inactivation in the liver
before exiting the body. Drug metabolism is generally broken down into two phases.
Phase I occurs when polar groups are attached to hydrophobic substrates via enzymes
that catalyze hydrolysis, reduction, and oxidation reactions. Phase II occurs when
enzymes, including UDP-glucuronosyltransferases and sulfotransferases, mediate
conjugation reactions where groups such as glucuronate, sulfate, glutathione, and amino
acids are conjugated to the drug (Iyanagi, 2007). These solubilized drug metabolites are
then eliminated from the body as less harmful waste products.
The human cytochrome P450 (CYP) family of hemoproteins are Phase I enzymes.
They are classified as monooxygenases which metabolize small molecule drugs and other
xenobiotics by oxidation. This oxidation results in the activation of prodrugs or the
inactivation and eventual clearance of other compounds. The CYP family consists of
nearly 60 members stratified into 18 families based on sequence homology (Nelson,
2009; Nebert, 2013).
The CYP3A Family
One important subfamily of CYPs, the CYP3A subfamily, is responsible for
approximately 50% of clinical drug detoxification in the liver (Zanger, 2013). The
CYP3A gene cluster is located on chromosome 7q22.1 and consists of 4 genes: CYP3A4,
CYP3A5, CYP3A7, and CYP3A43, and two pseudogenes: CYP3AP1 and CY3PAP2.
CYP3A4 is the most well-studied gene as it is highly expressed in the liver, with high
individual variability (>100-fold). The other three subfamily members, including
CYP3A5, are also expressed in the liver, but at lower levels than CYP3A4 (Zanger,
2013). A mass-spectrometric quantification of the CYP content of donor human liver
microsomes showed that of the total CYP3A protein measured, CYP3A4 made up 85.4%
and CYP3A5 made up 5.4% (Ohtsuki, 2012). CYP3A5 is expressed at low levels in the
liver and in extra-hepatic tissues such as the gastrointestinal tract, kidney, prostate,
adrenal gland, and lung (Raunio, 2005; Bolbrinker, 2012; Koch, 2002).
Not much is known about the regulation of CYP3A5, however, CYP3A5 has been
shown to be transcriptionally regulated by PXR, CAR, GR, VDR, and HNF4A (Burk,
2004; Maguire, 2012; Basseville, 2011; Hukkanen, 2003; Jover, 2001). One study
reviews the contrasting data about the inducibility of CYP3A5 and goes on to clearly
demonstrate how CYP3A5 is in fact inducible in hepatocytes via PXR and CAR in
response to drugs (Burk, 2004).
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Additionally, there is documentation of elevated CYP3A5 in certain cancer types,
such as adrenal cortical carcinoma (ACC), pancreatic cancer, colorectal cancer, and
ovarian cancer (Noll, 2016; Downie, 2005; Kumarakulasingham, 2005; Ma, 2018). With
this drug metabolism-associated gene being upregulated in cancer, it brings one to ask
what function it performs in cancer and by what mechanism.
Polymorphic CYP3A5
To address CYP3A5 functioning, one must consider the fact that CYP3A5 is
highly polymorphic. The wild type CYP3A5 allele, also called CYP3A5*1, contains 13
exons that are translated into a 502-amino acid protein (Figure 1-1). Single nucleotide
polymorphisms (SNPs) determine the genotype of CYP3A5, which determines expression
status, and therefore the activity of the enzyme. Four alleles exist for CYP3A5:
CYP3A5*1, CYP3A5*3, CYP3A5*6, and CYP3A5*7. CYP3A5*1 is the active, full length
transcript. CYP3A5*3 contains a SNP entitled rs776746, or 6986A>G, that dictates
activity. CYP3A5*1 contains an A in this position, where a G results in the inactive form
CYP3A5*3. CYP3A5*3 renders the protein inactive by revealing a cryptic splice site that
leads to a premature stop resulting in a truncated protein. CYP3A5*6 and CYP3A5*7 are
two null alleles that are less commonly found.
Many reports display the racial disparity of expression of active CYP3A5. Less
than 10% of Caucasians express active CYP3A5*1, while greater than 60% of African
populations express CYP3A5*1 (Zanger, 2013). In the normal liver CYP3A5 should be
largely dispensable since CYP3A4 can compensate for loss of CYP3A5 activity, as
CYP3A4 is the most prominent family member. An area in which this polymorphic
expression is of concern is drug administration regarding toxicity and response. Though
some propose CYP3A5 only plays a minor role in drug metabolism (Westlind-Johnsson,
2003), there is evidence that for some drugs, CYP3A5 is more important (Huang, 2004).
The dose administered and potential toxicity of the immunosuppressive drug tacrolimus
is associated with the genotype of CYP3A5. The intrinsic clearance of this drug is about
2-fold higher for CYP3A5 than CYP3A4. Individuals who are CYP3A5*1 expressers
show lower trough blood concentrations of tacrolimus, indicating that CYP3A5 plays a
leading role in its clearance (Dai, 2006). Doses must be clearly monitored to avoid lifethreatening nephrotoxicity that can occur if tacrolimus accumulates due to differences in
drug clearance. This principle could potentially affect cancer treatment as well. These
differences in functionality between these two main genotypes of CYP3A5 could
potentially have an impact on treatment options.
A recent paper demonstrates that CYP3A5 mediates basal and acquired drug
resistance in a patient-derived xenograft (PDX) pancreatic ductal adenocarcinoma
(PDAC) cell model (Noll, 2016). When treated with two tyrosine kinase inhibitors, knock
down (KD) of CYP3A5 via siRNA rendered the cells more sensitive to drug treatment.
Regarding regulation, this study demonstrates that basal expression of CYP3A5 is
mediated by HNF4A and drug-induced expression is mediated by PXR. This
transcriptional relationship between CYP3A5 and nuclear receptors is supported by
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Figure 1-1.

Splice Variants of CYP3A5

Schematic drawing of the gene and the cDNA structures of the major CYP3A5 alleles.
Exons are numbered and boxed. Exon 3B derived from an intronic sequence is labeled in
red.
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previous studies (Burk, 2004). Another interesting point is that PXR levels are correlated
with total CYP3A5 levels, but the correlation coefficients rise when you isolate
CYP3A5*1 expression. Targeting the HNF4A and/or PXR CYP3A5-regulatory pathways
could be one therapeutic option to increasing drug sensitivity in CYP3A5-expressing
tumors. Since CYP3A5 is upregulated in several cancer types, including hepatocellular
carcinoma (HCC), gastric carcinoma, and ACC (Noll, 2016), mechanistic studies could
reveal the factors responsible for this upregulation.
Splicing and PHF5A
The Spliceosome
The spliceosome is a large assembly of small nuclear RNAs (snRNAs) and
proteins that come together to form complexes called small nuclear ribonucleoproteins
(snRNPs) designated U1, U2, U4, U5, and U6. This molecular machine localizes to
nuclear speckles in eukaryotic cells and is the site for pre-mRNA splicing. Through a
cascade of events, the spliceosome is responsible for processing out introns and ligating
exons into mature mRNA that will be translated by the ribosomes into protein. The full
process is summarized in an elegant publication (Lodish, 2000). Of interest to this project
is the step in which U2 binds the branch point adenosine (BPA) to initiate lariat
formation. The U2 snRNP is made up of the SF3A and SF3B subcomplexes. One of the
SF3B proteins is called PHF5A. Along with PHF5A, SF3B1 and SF3B3 contain residues
that make up the binding site for splicing modulators such as Pladienolide B,
Herboxidiene, the Sudemycins, and Spliceostatin A. These compounds inhibit formation
of the spliceosome and have been used to target the spliceosome as a cancer treatment by
inducing apoptosis in tumor cells (Kashyap, 2015; Martinez-Montiel, 2016).
PHF5A
PHF5A is a small 12 kD protein in the PHD-domain containing protein family.
While the PHF5A transcript contains some variability between species, the protein
sequence in all vertebrates tested is 100% identical (Oltra, 2003) and is ubiquitously
expressed in all tissues (Falck, 2013). PHF5A has seemingly diverse functions. One
published mechanism for PHF5A is its role as a transcriptional cofactor. One study
proposes that the PHF5A protein localizes to the nucleus and binds the proximal
promoter of Connexin43 (Cx43), enhancing the response of Cx43 to estrogen (Oltra,
2003). A recent paper identifies PHF5A as a DNA-RNA-binding protein (DRBP)
(Conrad, 2016). This paper proposes that PHF5A is a DRBP that couples RNA splicing
to transcription, since it binds to Cx43 and acts as a bridge between splicing proteins and
helicases (Rzymski, 2008). Another name for PHF5A is SF3b14b, which was identified
as a member of the SF3b complex, a part of the U2 snRNP of the spliceosome (Will,
2002). A recent review mentions several compounds reported to inhibit the spliceosome,
several by targeting the SF3B1 subunit (Effenberger, 2017). Two of these inhibitors are
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Pladienolide B and Herboxidiene. PHF5A also stabilizes the polymerase-associated
factor 1 complex (PAF1C). The human PAF1C is a 6-membered protein complex
responsible for transcriptional elongation and is made up of PAF1, CDC73, WDR61,
LEO1, RTF1, and CTR9. Interestingly, PAF1 is a marker that is expressed on pancreatic
cancer stem cells (CSCs), and may play a role in CSC self-renewal and drug resistance of
these pancreatic CSCs (Vaz, 2014). PHF5A stabilizes the PAF1C and knocking down
PHF5A results in disruption of the PAF1C and decreased transcriptional elongation of
PAF1C target genes (Strikoudis, 2017).
Hypothesis and Specific Aims
We hypothesize that additional regulatory mechanisms exist for CYP3A5.
Knowledge of these mechanisms could lend insight into therapeutic targets to overcome
drug resistance, as well as adding to the body of knowledge of CYP3A5 regulation. The
goal of this study is two-fold: 1) to perform a transcription factor and chromatinassociated protein siRNA screen for potential regulators of CYP3A5 in a PDAC cell
model, 2) to follow up on top screen hits, such as PHF5A, and identify the mechanism of
their regulation.
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CHAPTER 2.

MATERIALS AND METHODS
Cell Culture

The cell lines AsPC-1 (CRL-1682), HPAF-II (CRL-1197), PANC-1 (CRL-1469),
MIA PaCa-2 (CRL-1420), SU.86.86 (CRL-1837), CAPAN-2 (HTB-80), CFPAC-1
(CRL-1918), Panc02.13 (CRL-2554), HCT 116 (CRL-247), HEPG2-C3A (CRL-10741),
and LS180 (CL-187) were obtained from the American Type Culture Collection (ATCC;
Manassas, VA). SNU-C4 cells were obtained from KCLB (Cat# 0000C4, KCLB). Huh-7
cells were a gift from a collaborator from Japan. Cells were cultured in media per ATCC
website media suggestions with FBS (HyClone; Logan, UT) and 1% PenicillinStreptomycin (Life Technologies). Regarding passaging, cells were washed with 1X PBS
(Gibco), trypsinized for 3-5 min, and neutralized with cell-type specific media. Cells
were counted and 2-3 mil cells, depending on the cell type, were passaged into a new T75 flask. Plating media for immunofluorescence experiments was RPMI-1640 without
phenol red or antibiotics and supplemented with 10% FBS. Cells were cultured and
maintained in a humidified incubator at 5% CO2 at 37 °C.
siRNA
SMARTpool siGENOME siRNA sets were used to target the following
transcripts (Dharmacon): CYP3A5 (M-009684-01-0005), NR1I2 (M-003415-02-0010),
HNF4A (M-003406-02-0005), PHF5A (M-014987-01-0005), SMARCD1 (M-01724401-0005), ZNF354A (M-007685-01-0005), BARX2 (M-012395-01-0005), CDX2 (M015636-01-0005), GTF3C1 (M-012581-01-005), ZNF397 (M-014870-00-0005), ZFHX3
(M-015412-01-0005), KDM5A (M-003297-03-0005), PPARG (M-003436-02-0005),
CREBBP (M-003477-02-0005), GATA3 (M-003781-01-0005), HIF1A (M-004018-050005), MED17 (M-006312-02-0005), RNF112 (M-006588-01-0005), KLF13 (M006994-01-0005), SLC4A10 (M-007580-01-0005), TFAP4 (M-009504-00-0005),
CDY2A (M-010346-01-0005), NOTCH2 (M-012235-00-0005), SF3B1 (M-020061-020005), SF3B3 (M-020085-01-0005), PAF1 (M-020349-01-0005), WDR61 (M-01461400-0005), CDC73 (M-015184-00-0005), CTR9 (M-032246-01-0005), LEO1 (M-01657900-0005), and RTF1 (M-014104-01-0005). Individual siNT5 was used as a control
siRNA in all experiments (Dharmacon). For the top 5 hit siRNA deconvolution, the
following siGENOME sets of 4 were used (Dharmacon): PHF5A (MQ-014987-01-0002),
SMARCD1 (MQ-017244-01-0002), ZNF354A (MQ-007685-01-0002), BARX2 (MQ012395-01-0002), and CDX2 (MQ-015636-01-0002).
siRNA Transfection
For qPCR and western blotting readout experiments, cells were counted in
duplicate using the Cellometer Auto T4 (Nexcelom Bioscience). Per well, 5x105 cells in
2 ml media, media according to cell type, were seeded in 6-well plates (Corning Costar)
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for reverse transfection using the RNAiMAX transfection protocol (Invitrogen). For a 6well plate, 2 ml was the total volume per well: 400 µl transfection solution and 1600 µl
growth media. The transfection solution for one well consisted of the following: 400 µl
Opti-Mem, 6 µl RNAiMAX, and 250 nM siRNA. First, 6 µl RNAiMAX was diluted in
200 µl Opti-MEM and mixed well. Second, 5 µl siRNA from 10 µM stock was diluted in
200 µl Opti-MEM and mixed (ex: 5 µl of a 10 µM stock siRNA solution goes into 400 µl
transfection solution). Third, the two tubes were combined, mixed well, and incubated for
10-15 min at room temperature. siRNA was used at a final concentration of 25 nM. 2 ml
media per well was added 24 hr post-transfection. 72 hr post transfection, media and cells
were collected and downstream RNA isolation and qPCR was performed. When double
KD was employed, and equal amount of siNT was supplemented in control wells to
equalize the total amount of siRNA in each well.
For immunofluorescence optimization experiments, reverse transfection was also
used. The cell suspension was pipetted through a cell strainer to achieve single cells, then
25 µl media containing 1.5x104 cells was seeded per well in 96-well plates (Cell Carrier),
overlaying siRNA with a final concentration of 25 nM. Each well contained 5 µl 250 nM
siRNA, 20 µl OPTI-Mem, and 0.2 µl RNAiMAX. 24 hr later, 50 µl media was added.
For lipid optimization, RNAiMAX (Invitrogen) and red and blue Dharmafect
(Dharmacon) were tested. 72 hr post-transfection, cells were collected and downstream
RNA isolation and qPCR was performed, see “RNA Isolation and qPCR” section below.
TaqMan qPCR Probes
For qPCR, 20X FAM-labeled TaqMan probes (ThermoFisher) were used to detect
target gene expression. The TaqMan probes used were as follows: CYP3A5
(Hs01070905_m1), PHF5A (Hs00992149_g1), HNF4A (Hs00230853_m1), NR1I2
(Hs1114267_m1), SMARCD1 (Hs00161980_m1), ZNF354A (Hs01921591_s1), BARX2
(Hs00186346_m1), CDX2 (Hs01078080_m1), GTF3C1 (Hs00155360_m1), ZNF397
(Hs01061031_m1), ZFHX3 (Hs00199344_m1), KDM5A (Hs00231908_m1), PPARG
(Hs01115513_m1), CREBBP (Hs00932878_m1), GATA3 (Hs00231122_m1), HIF1A
(Hs00153153_m1), MED17 (Hs00188669_m1), RNF112 (Hs00993289_g1), KLF13
(Hs00429818_m1), SLC4A10 (Hs00222849_m1), TFAP4 (Hs01558245_m1), CDY2A
(Hs00371558_s1), NOTCH2 (Hs01050702_m1), SF3B1 (Hs202782_m1), SF3B3
(Hs01035537_m1), PAF1 (Hs219496_m1), WDR61 (Hs228800_m1), CDC73
(Hs363810_m1), CTR9 (Hs00206060_m1), LEO1 (Hs292080_m1), RTF1
(Hs385532_m1), and GAPDH (Hs99999905_m1) as an endogenous gene expression
control for target gene mRNA levels.
RNA Isolation and qPCR
Total RNA was extracted using the Maxwell 16 LEV simplyRNA Tissue Kit with
the Maxwell 16 Research Instrument (Promega). Nucleic acid concentration was
measured using the NanoDrop 8000 UV-Vis Spectrophotometer (ThermoFisher
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Scientific). RNA was converted to cDNA by using the SuperScript VILO cDNA
Synthesis Kit (Life Technologies). Target gene mRNA expression was detected by using
20X FAM-labeled TaqMan probes (ThermoFisher), Fast Advanced Master Mix (Life
Technologies), and quantitated via the 7900HT Fast Real-Time PCR System (Applied
Biosystems). The real-time PCR protocol found on page 14 of the TaqMan Fast
Advanced Master Mix User guide, linked here
https://tools.thermofisher.com/content/sfs/manuals/cms_084554.pdf, was followed
exactly. Hold for 2 min at 50 °C, hold for 20 sec at 95 °C, and 40 cycles of 1 sec at 95 °C
and 20 sec at 60 °C. 10.5 µl reactions (per well) were used as follows: 5 µl Fast
Advanced Master Mix, 0.5 µl target gene TaqMan probe, 10 ng cDNA in a 5 µl
H2O/cDNA dilution. The fold-change in expression was calculated by using the
comparative Ct (ΔΔCt) method, with the values of controls set to one (siNT5). All
samples for every qPCR were tested in technical triplicate.
Western Blotting
Cells were lysed with Pierce RIPA buffer (ThermoFisher) plus Complete Mini
protease inhibitor tablets (Roche) and incubated on ice for 1 hr, followed by sonication at
50% amplitude for a 5 sec pulse. Lysates were spun down at 16.2 xg for 5 min at 4 °C.
Protein concentration was measured using the Pierce BCA Protein Assay kit
(ThermoFisher). Protein samples were boiled in NuPAGE LDS 4X Sample Buffer (Life
Technologies) for 5 min at 95 °C and subjected to gel electrophoresis using 4-12% BisTris gels in 1X NuPAGE MES-SDS running buffer (Invitrogen). The resulting gels were
transferred onto nitrocellulose membranes using the iBlot dry transfer system
(Invitrogen). Membranes were blocked for 1 hr at room temperature (RT) with Odyssey
blocking buffer PBS (LI-COR). The primary antibodies used were anti-cytochrome P450
3A5 antibody at 0.24 µg/ml (ab108624, ABCAM), anti-PHF5A at 0.24 µg/ml (15554-1AP, Proteintech), anti-SF3B1 at 4 µg/ml (ab172634, ABCAM), and anti-β-actin 0.04
µg/ml (A5441, Sigma). Primary antibody was diluted in blocking buffer and membranes
incubated overnight at 4 °C. The following morning membranes were incubated with
species-specific infrared dye-conjugated secondary antibodies at a 1:10,000 dilution (LICOR) for 1 hr at RT. 1X TBS-T was used to wash membranes 5 min 3X after incubation
with both primary and secondary antibodies. Antibody-bound proteins were visualized
using the Odyssey CLx (LI-COR). When necessary, membranes were stripped with 10 ml
NewBlot Nitro Stripping Buffer 5X (LI-COR).
CYP3A5 Genotyping
Raw DNA was isolated via the High Pure PCR Template Preparation Kit protocol
(Cat# 11796828001, Roche). To sequence the region of the CYP3A5 gene where the
rs776746 SNP is located, two rounds of PCR were performed and the resulting PCR
product was sequenced. First, the CYP3A5 gene (GenBank Accession #NG_000004.2)
was amplified from the proximal promoter region to exon 7. Genomic DNA (300 ng) was
amplified using 25 µl 2X Phusion High Fidelity PCR Master Mix with GC Buffer (New

8

England BioLabs, Cat# M0532S) with 1 µl of 100 µM each primer (Ztaq-pro-Ex7,
forward and reverse) listed in Table 2-1. All genotyping primers were standard, desalted
oligos (ThermoFisher Scientific). The first-round PCR: 2 min at 95 °C, 30 cycles of 10
sec at 98 °C, 10 sec at 55 °C, 4 min at 72 °C, and a 10 min final extension of 72 °C.
Next, intron 3 was amplified by 2X Phusion with 1 µl of 100 µM Intron 3 primers
(Table 2-1). Second-round PCR consisted of 5 min at 94 °C, followed by 30 cycles of 15
sec at 94 °C, 15 at 55 °C, 1 min at 72 °C, with a 10 min final extension of 72 °C. The
PCR products were run out on a 2% agarose gel, cut out, and purified with the QIAquick
Gel Extraction Kit (Qiagen, Cat# 28704). The resulting PCR product was Sanger
sequenced using the second round Intron 3 primers to detect the identity of the SNP.
384-well Cell Number Determination
AsPC-1 cells were seeded in a CellCarrier-384 Ultra Microplate (Perkin Elmer) at
concentrations of 6, 4, 2, and 1 thousand cells per well with 6 replicates of each cell
dilution in 25 µl plating media. Cell proliferation was monitored by using an IncuCyte
ZOOM live-cell imaging system (Essen BioScience; Ann Arbor, MI). One image per
well was captured every 3 hr for 72 hr. The percentage of confluent cells was calculated
by using IncuCyte software.
Immunofluorescence Screen Conditions
For optimization experiments, 96-well plates were used. AsPC-1 cells (1.5x104
cells in 25 µl media, per well) were seeded in 96-well plates (Cell Carrier), see “siRNA
Transfection” section above for transfection details. For screening, 384-well plates were
used to facilitate high-throughput, automated use. Briefly, an Aligent Biocel was used to
perform an automated, high-throughput siRNA screen. An Aligent Bravo was used to
stamp siRNA in assay plates, a Wellmate was used to dispense cells in media into the
plates, and the plates were incubated at 37 °C in Liconic incubators. Each well contained
2.5 µl 250 nM siRNA, 10 µl Opti-MEM, and 0.1 µl RNAiMAX. Cells were collected and
pipetted through a cell strainer, counted in duplicate, and made up to a concentration so
that there were 15 µl cell solution per well with a total volume of 25 µl in each well and
6,000 cells per well. The Dharmacon siTF library contained 6 plates, including 1 dummy
plate. Controls were placed in columns 1, 2, 23, 24: 10 µl 250 nm siRNA with 32 wells
siNT5 and 32 wells siCYP3A5. Plate barcodes were scanned before use. After 24 hr, 25
µl 10% FBS plating media was added to each well (Wellmate). Plate sets were fixed 48
and 72 hr post transfection. Set 3 was fixed at 48 hr, and sets 1 and 2 were fixed at 72 hr
with paraformaldehyde at 4% final concentration for 20 min at RT. Cells were
permeabilized with 0.25% final concentration Triton X-100 in PBS for 15 min. Cells
were then blocked with Odyssey blocking buffer PBS for 1 hr at RT. The fixed cells were
subjected to staining with anti-CYP3A5 antibody at 0.3 µg/ml (ab108624, ABCAM)
overnight at RT. The cells were then washed with cold 1X PBS-T and incubated with
Alexa 647-labeled anti-rabbit secondary antibody (1:1000) (Invitrogen) at RT and DAPI
at 5 µg/ml for 1 hr. For whole-cell staining, the cells were subsequently incubated with
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Table 2-1. Primer Sequences for CYP3A5 Genotyping
Round

Primer Name

Forward Primer (5’ to 3’)

Reverse Primer (3’ to 5’)

1st round

Ztaq-pro-Ex7

2nd round

Intron 3

TATCTGTAATAATATGGATG
GAACTG
ATGGAGAGTGGCATAGGAGA
TACC

CTTGTTCTAAACATAAG
TTCTCTGTC
CCATACCCCTAGTTGTA
CGACACA
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CytoPainter Phalloidin-iFluor 488 Reagent (1:4000) (Cat# ab176753, ABCAM) for 1 hr
at RT. The cells were examined and analyzed by fluorescence microscopy using the
InCell Analyzer (GE) and Dr. Yueming Wang performed batch analysis on the data.
Cell Proliferation Assay
Real-time cell growth in response to DMSO and splicing inhibitors was measured
as the degree of cell confluence over time in culture plates. Confluence was determined
using an IncuCyte HD live-cell imaging system (Essen BioScience). Cell densities for the
growth curve determination were serially diluted 1:2 from 4 k to 0.5 k in 0.1% DMSO.
Cells were plated in 96-well plates (Cell Carrier) leaving the edge wells with only plain
media. Images were taken every 3 hr for 120 hr, 4 images per well. Cell proliferation
curves were plotted using confluence values at specified time points for each treatment.
For the cell growth studies upon splicing inhibitor addition, 4 k cells/well were plated in
96-well plates and 12 hr later, drugged with dilutions of drug, labeled time zero for the
graphs. Immediately after drugging, 4 images per well were taken every 3 hr for 120 hr.
These data were analyzed with the IncuCyte ZOOM software. Pladienolide B (CAS
445493-23-2) was purchased from Santa Cruz Cat# sc-391691, and Herboxidiene (CAS
142861-00-5) from Focus Biomolecules Cat# 10-1614-0200.
Inducible shRNA
A doxycycline-inducible PHF5A shRNA plasmid was constructed as previously
described (Wiederschain, 2009; Wee, 2008)), using the pLKO-Tet-On parent plasmid
(Tet-pLKO-puro, gift from Dmitri Wiederschain, Addgene plasmid #21915). Primers
were designed using the nucleotide sequence of siPHF5A #2
(GCATATGTGATGAGTGTAA); catalog number for Set of 4 siRNAs is MQ-01498701-0002, siRNA #2 was the siRNA used as the basis for this experiment (Dharmacon).
Forward primer sequence:
CCGGGCATATGTGATGAGTGTAACTCGAGTTACACTCATCACATATGCTTTTT.
Reverse primer sequence:
AATTAAAAAGCATATGTGATGAGTGTAACTCGAGTTACACTCATCACATATG
C. Oligos/primers were ordered from ThermoFisher Scientific. Briefly, a double
restriction enzyme digest was performed with EcoRI and AgeI to release the stuffer from
the pLKO-Tet-On parent plasmid. The digested vector was ligated with the shPHF5A #2
oligos with T4 DNA ligase (Cat# M0202S, New England Biolabs) and incubated for 2 hr
at RT, then overnight at 16 °C. Ligation was transformed into NEB Competent cells per
protocol and single clones were sequenced to ensure the oligos were incorporated
correctly (Figure 2-1). Lentivirus was generated in Lenti-X 293T cells (Cat# 632180,
Clontech) in 10 cm plates. To package the virus, the following was combined: 6 µg
pLKO vector containing shPHF5A#2, 4.5 µg psPAX2 (gift from Didier Trono, Addgene
plasmid #12260), and 3 µg pMD2.G (gift from Dider Trono, Addgene plasmid #12259)
with FuGENE 6 per protocol (Promega) in Opti-MEM for transfection. The transfection

11

Figure 2-1.

Sequence Confirmation of shPHF5A Incorporation

Alignment of the forward primer sequence designed from siPHF5A #2 and 4 clones of
the tet-pLKO-puro plasmid containing shPHF5A. Clones labeled JDH091-094.
MegAlign software was used for alignment.
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medium was replaced with fresh medium after 24 hr and viruses were collected after 48
hr. To remove cells and debris, the medium was filtered with a 0.45 µm PES filter,
aliquoted, and frozen at −80 °C. For viral transduction, 1 ml of virus-containing medium
mixed with 1 ml of fresh medium was added to a 6-well plate of AsPC-1 at 500 k
cells/well with 8 µg/ml Sequa-brene (Cat# S2667, Sigma) overnight. The transduction
medium was replaced with fresh medium containing 0.3 µg/ml puromycin
dihydrochloride (Cat# P9620, Sigma) 24 hr later. The cells were grown in culture for 1
week to establish pooled puromycin-resistant stable cells, changing media every 2 days.
To maintain the pooled stable cells for future experiments, 0.15 µg/ml of puromycin was
used thereafter. For induction, the cells were grown in medium with tetracycline-free
FBS (Clontech) before the addition of doxycycline. To induce shRNA expression in
inducible stable cells, doxycycline was added to the culture medium
PHF5A Knock Out in AsPC-1 Cells
Glycerol stocks of 4 PHF5A guide RNAs were picked from the LentiArray
Human Epigenetics CRISPR Library, Glycerol (Invitrogen). They are located in plate
10927, well B3 in rows 1-4, stored at -80 °C. Bacteria was streaked from glycerol stocks
onto LB-ampicillin plates. Single colonies were picked and shaken overnight in 4 ml LBamp broth at 37 °C at 200 RPM in a MaxQ 4450 incubated shaker (ThermoFisher
Scientific). DNA was isolated from cultures using the QIACube system (Qiagen). DNA
was packaged into lentivirus via the protocol stated above. AsPC-1 Cas9-expression
stable cells were transduced with the guide viruses AsPC-1. 24 hr later the media was
changed. 48 hr after transduction, puromycin selection was initiated at 3 µg/ml, with a
“no-transduction” control well. Media was changed every two days for six days to allow
for recombination.
PXR Knock Out in AsPC-1 Cells
To generate a PXR knock out (KO) AsPC-1 cell line, the CRISPR/Cas9 sc400824 and sc-400824-HDR plasmids were used (Santa Cruz Biotechnology, Inc.). The
“CRISPR / Cas9 KO Plasmid and HDR Plasmid Transfection” protocol from Santa Cruz
Biotechnology, Inc. (https://datasheets.scbt.com/protocols/CRISPR_protocol.pdf) was
followed exactly, with the initial puromycin selection concentration being 3 µg/ml.
Colonies were expanded from single clones in 48-well plates.
RNAseq
AsPC-1 cells were transfected in 6-well plates in triplicate with either lipid-only
RNAiMAX control, siNT5, or siPHF5A pool. Reagent volumes are identical to the 6well protocol found in the “siRNA Transfection” section above. siRNA was used at a
final concentration of 25 nM. Total RNA was isolated from the AsPC-1 transfected cells,
for isolation see “RNA Isolation and qPCR” section. The Nanodrop 8000 was used not
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only to determine concentration of RNA, but to ensure purity of the RNA. Library prep
was done by Dr. Rain Sun and RNAseq was performed by Dana Roeber on a HiSeq 4000
(Illumina). Resultant stranded paired-end 100-bp sequences were mapped to the hg19
human genome with the STRONGARM pipeline developed for the Pediatric Cancer
Genome Project34 and counted with HTSEQ. Statistical testing to determine differential
expression was performed in R by using the voom and limma packages. By using our
rnapeg in-house tool, exon junction reads were extracted to visualize alternative splicing
and select differential junctions and to complement multivariate analysis of transcript
splicing (MATS) 3.0.8 (python 2.7.2)36. Principle component analyses was produced
with Partek Genomics Suite 6.6. RNAseq initial analysis was performed by Dr. David
Finkelstein.
Volcano Plot
Volcano plot was generated in Graphpad PRISM by plotting statistically
significant, differentially expressed genes after removal of any genes affected by the
siNT treatment. Statistically significant genes were plotted as a function of -log10
(adjusted p-value), and differential gene expression was plotted as a function of log2
(Fold change / siNT). Genes determined to be statistically significant and (1) downregulated were highlighted in green, or (2) up-regulated were highlighted in red, as
determined by -log10(p-value) ≥ 1 and Log2(FC) ≤ -1 or ≥ 1. Volcano plot was generated
by William C. Wright.
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CHAPTER 3.

RESULTS

Genotyping CYP3A5
To understand which isoform(s) of CYP3A5 each cell line expresses, the
following PDAC cell lines were genotyped: AsPC-1, HPAF-II, PANC-1, MIA PaCa-1,
CFPAC-1, CAPAN-2, SU.86.86, and Panc02.13. Additionally, several other GI cancers
and hTERT-HPNE cell lines were genotyped. HUH-7 cells were used as a control as this
line is homozygous CYP3A5*3/*3 (Dorr, 2017). The genotyping protocol was adapted
from a protocol previously described (Saeki, 2003). All of the lines genotyped were
homozygous CYP3A5*3/*3 (G) at the site of the SNP (Table 3-1), however, HCT116
will need to re-genotyped as it was only performed once and is potentially a heterozygous
at this site. Examples of electropherograms for each cell line are found in Figure 3-1. As
CYP3A5*3 protein is not detectable or expressed, isoform-specific probes were utilized
by Dr. Ogheneochukome Lolodi to ensure that both CYP3A5*1 and CYP3A5*3 were
expressed on the mRNA level in AsPC-1 cells. Bands were detected at both amplicon
sizes, confirming the presence of both isoforms (data not shown). CYP3A5*1 protein can
be detected via qPCR and western blotting in 6 of the 8 PDAC cell lines used in this
study (Figure 3-2A,C). The samples in lanes 10 and 11 (Figure3-2C) are from inducible
CYP3A5 KD cells and overexpression stable AsPC-1 cell lines. They are included as
expression controls and were provided by Dr. O. Lolodi.
Transcription Regulation of CYP3A5
To paint a clearer picture of what genes regulate CYP3A5 expression, a highthroughput screen was designed. The AsPC-1 PDAC cell line was chosen as a screening
model because it has high basal CYP3A5, PXR, and HNF4A expression (Rouillard,
2016), which was confirmed via RNAseq by Dr. Peter Oladimeji (data not shown).
First, a published regulator of basal CYP3A5 expression, HNF4A, was tested in
AsPC -1 cells (Noll, 2016). Cells were transfected with siRNA targeting HNF4A and/or
PXR, since PXR is downstream of HNF4A. It was found that at 72 hr post-transfection
neither siHNF4A nor siPXR decrease basal CYP3A5 levels at the mRNA or protein
levels in AsPC-1 cells, as measured by western blotting and qPCR (Figure 3-3A-B).
Knock down efficiency was greater than 70% for the putative regulators: PHF5A
(Figure 3-3C), HNF4A (Figure 3-3D), and PXR (Figure 3-3E). Next, this observation
was tested in 5 other ATCC PDAC cell lines: HPAF-II, Panc02.13, SU.86.86, CFPAC-1,
and CAPAN-2. In all cases, CYP3A5 levels are unchanged when HNF4A and PXR are
knocked down. This is shown via western blotting (Figure 3-4A-D) and qPCR
(Figure 3-4E-I) for each cell line. Western blot data is not shown for CAPAN-2 as
CYP3A5 protein expression was undetectable, therefore, only qPCR data is shown
(Figure 3-4H).
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Table 3-1. CYP3A5 Genotyped Cell Lines
Cell Line
Cell Type
Genotype
AsPC-1
PDAC
G/G
HPAF-II
PDAC
G/G
PANC-1
PDAC
G/G
MIA PaCa-1
PDAC
G/G
CFPAC-1
PDAC
G/G
CAPAN-2
PDAC
G/G
Su.86.86
PDAC
G/G
PANC02.13
PDAC
G/G
hTERT-HPNE “normal” ductal
G/G
HUH-7
HCC
G/G
LS180
CRC
G/G
SNU-C4
CRC
G/G
HCT 116
CRC
A/G*
HepG2-C3A
HCC
G/G
*needs further testing
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Figure 3-1.

CYP3A5 rs776746 SNP Electropherograms

Electropherograms revealing the genotype of CYP3A5 regarding the 6986A>G SNP in 8
PDAC cell lines and 6 other cell lines.

17

Figure 3-2.

CYP3A5 and PHF5A Expression in 8 PDAC Cell Lines

A. qPCR data showing CYP3A5 relative expression, plotted as 2^-dCt. B. qPCR data
showing CYP3A5 relative expression, plotted as 2^-dCt. C. Western blot of CYP3A5,
PHF5A, and β-actin primary antibodies. Lanes 10 and 11 contain inducible CYP3A5 KD
and expression constructs, respectively, provided by Dr. O. Lolodi. 45 µg protein loaded
per lane.
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Figure 3-3. siPHF5A, but Not siPXR/siHNF4A, Affects Basal CYP3A5 Expression
in AsPC-1 Cells
AsPC-1 cells were treated with a final concentration of 25 nM for 72 hr. A. Western blot
of CYP3A5 and β-actin primary antibodies. 50 µg protein loaded per lane. B-E. Fold
change represents 2^ddCt, normalized to GAPDH of siNT5. B. CYP3A5 expression. C.
PHF5A expression. D. HNF4A expression. E. PXR expression.
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Figure 3-4. siPHF5A, but Not siPXR/siHNF4A, Affects Basal CYP3A5 Expression
in 5 PDAC Models
PDAC lines, HPAF-II, Panc02.13, SU.86.86, CFPAC-1, and CAPAN-2, were treated
with a final concentration of 25 nM for 72 hr. A-D. 50 µg protein loaded per well.
Western blot of CYP3A5, PHF5A, and β-actin primary antibodies. Lane labels of siRNA
in A apply to B-D as well. E-I. qPCR results for CYP3A5, PHF5A, PXR, and HNF4A
using ddCt method. WB data for CFPAC-1 not shown.
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To determine what factors affect CYP3A5 expression in PDAC cell lines, an
siRNA screen was performed. Before running the screen, a series of experiments was
undertaken to optimize screening conditions. To confirm the mRNA and protein levels of
CYP3A5 in AsPC-1 and the knockdown efficiency of the siRNA, cells were seeded into
6-well plates, reverse transfected with control siNT4 and siCYP3A5, and collected 48 hr
later. siRNA was used at a final concentration of 25 nM. Lysed samples were analyzed
via qPCR and western blotting to detect knockdown of CYP3A5. CYP3A5 was
detectable at both the mRNA and protein levels, and expression was successfully
knocked down up to 70% via qPCR (Figure 3-5A) and western blotting (Figure 3-5B).
To select the most desirable non-targeting siRNA control, an siNT optimization
experiment was performed. AsPC-1 cells were reverse transfected with siNT1, siNT2,
siNT3, siNT4, and siNT5, and 48 hr later examined via measuring CYP3A5
immunofluorescence intensity (Figure 3-5C). siRNA was used at a final concentration of
25 nM. Results highlighted the range of variability that “non-targeting” controls can
exhibit. siNT2 and siNT5 were found to behave similarly to lipid controls, therefore,
siNT5 was chosen as the NT control for all future experimentation.
To obtain maximum transfection efficiency to ensure a good fluorescence signal
window, a lipid optimization experiment examined the efficiency of the lipids:
RNAiMAX, red Dharmafect, and blue Dharmafect. Four wells per treatment were
collected to analyze gene expression. Immunofluorescence showed that RNAiMAX and
the blue Dharmafect yielded slightly better CYP3A5 signal knockdown that red
Dharmafect, so RNAiMAX was selected for use in future experiments (Figure 3-5D).
Representative images of RNAiMAX-transfected cells are shown in Figure 3-5E.
To determine what timepoint yielded superior knockdown of CYP3A5, a
comparison siRNA experiment was performed to test KD at 48 and 72 hr. It was found
that CYP3A5 mRNA levels are more efficiently decreased at 72 hr (Figure 3-5F).
To optimize the dilution of primary CYP3A5 antibody used for screening, an
antibody titration experiment was performed. A serial dilution from 1:100 to 1:8000 was
used and plates were scanned for CYP3A5 immunofluorescence. The amount of antibody
used greatly affected the signal window and intensity, with 1:100 having the greatest
intensity, but the middle range dilutions having better separation between siNT5 and
siCYP3A5 treatments, therefore, a dilution of 1:400 was selected for the final screening
conditions (Figure 3-5G).
Once conditions were optimized, miniaturization to 384-well from 96-well plates
was undertaken. To ascertain the appropriate cell density of AsPC-1 cells in a 384-well
plate, cells were seeded with decreasing cell number and incubated for 72 hr. Using the
IncuCyte Zoom, endpoint images were taken and it was determined that 6,000 cells/well
is the optimal number of cells for immunostaining AsPC-1 (Figure 3-5H).
To address CYP3A5 regulation, a high-throughput siRNA screen of ~1,500
transcription factors and chromatin-associated proteins was performed in the AsPC-1
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Figure 3-5.

High-Throughput siRNA Screening Condition Optimization

A-B. AsPC-1 cells transfected with 10 nM final concentration control siNT4 or
siCYP3A5 for 48 hr. A. Gene expression was analyzed via qPCR normalized to GAPD
using the ddCt method. B. Western blot of CYP3A5 and β-actin primary antibodies. C.
AsPC-1 cells were treated with 10 nM final concentration siNT1-5 for 48 hr and stained
with CYP3A5 primary antibody. 24 fields per treatment were analyzed using the InCell
Analyzer. D-E. AsPC-1 cells were reverse transfected with a final concentration of 25 nm
siRNA to CYP3A5, NT4, and a lipid-only control. Lipids tested were RNAiMAX, red
Dharmafect, and blue Dharmafect. D. CYP3A5 fold change over GAPDH normalized to
siNT4. E. Cells were stained with primary anti-CYP3A5 antibody (1:75), secondary
Alexa Fluor 647 (1:1000), DAPI, and Phalloidin-488 (1:1000). 48 hr timepoint. 20X
representative images from RNAiMAX-transfected cells. Images displaying red channel
(CYP3A5 staining). Image E1. Lipid only control, E2. siNT4, and E3. siCYP3A5. F.
AsPC-1 cells were reverse transfected with 25 nm siRNA to CYP3A5 and siNT5. Fold
change over GAPDH normalized to siNT5 control. Cells were collected 48 and 72 hr
post-transfection. CYP3A5 fold change is shown. G. AsPC-1 cells were reverse
transfected with 25 nm siRNA to CYP3A5 and siNT5. Cells were stained with primary
anti-CYP3A5 antibody in a serial dilution, secondary Alexa Fluor 647 (1:1000), DAPI,
and Phalloidin-488 (1:1000). 12 fields per well were analyzed. Shown is the normalized
CYP3A5 intensity. H. AsPC-1 cells were seeded into a 384-well plate and incubated for
72 hr. 10X images and confluence percentages taken by IncuCyte Zoom 77 hr postplating. Average confluence of 6 well per density is shown: (1). 6K cells/well, average
confluence 30.4% (2). 4K cells/well, average confluence 18.9% (3). 2K cells/well,
average confluence 11.4% (4). 1K cells/well, average confluence 4.6%.
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cell line. The screen’s readout was CYP3A5 immunofluorescence, with the desired result
being the identification of putative positive regulators. Positive regulatory hits would
have decreased CYP3A5 signal upon KD of the aforementioned regulators.
Optimizations were carried out before the screen to determine the following: cell number,
primary antibody concentration, suitable secondary, secondary antibody concentration,
suitable whole-cell stain, stain concentration, conditions for fixation, blocking, washing,
permeabilization, and transfection duration, key points shown in Figure 3-5.
Screen Analysis
Once the screen was completed, Dr. Yueming Wang scanned each of the 18 plates
according to an InCell analysis protocol. Briefly, cell location was determined by DAPI
staining and object segregation. Cell number/area was determined by phalloidin (green
channel) and object segregation. Total CYP3A5 level was determined by the average
intensity of CYP3A5 (red channel) per cell in each well multiplied by the total area. This
total calculated CYP3A5 level was then divided by total cell area to achieve normalized
CYP3A5 level. This normalized total CYP3A5 level is used for statistical analysis and
quality control. An example of this masking is found in Figure 3-6A. This analysis
yielded strictly standardized mean difference (SSMD) values which were used for QC
and hit selection (Figure 3-6B).
Hit Selection and Top 20 Hits
Based on SSMD, visual downregulation, and cell number, the following 20 hits of
interest were selected: PHF5A, SMARCD1, ZNF354A, BARX2, CDX2, GTF3C1,
ZNF397, ZFHX3, KDM5A, PPARG, CREBBP, GATA3, HIF1A, MED17, RNF112,
KLF13, SLC4A10, TFAP4, CDY2A, and NOTCH2. Pooled siRNA was tested for each
of the 20 hits and the subsequent CYP3A5 levels were detected via western blotting
(Figure 3-7A-D) and qPCR (Figure 3-7E-F). Many of the top 20 hits were validated as
positive regulators of CYP3A5 expression, meaning that that when the gene of interest
was knocked down, CYP3A5 levels correspondingly deceased. This indicates that the
screen produced a good set of hits in line with the desired phenotype.
Top 5 siRNA Deconvolution
Of the top 20 hits that were validated as positive regulators, 5 were chosen for
siRNA deconvolution: PHF5A, BARX2, ZNF354A, CDX2, and SMARCD1. siRNA
deconvolution ensures that the best individual siRNAs producing maximal KD are
identified for future use. AsPC-1 cells were reverse transfected with a final concentration
of 25 nM siRNA, with each gene having 4 individual siRNAs (Figure 3-8). Upon
deconvolution it was found that the individual siRNAs targeting PHF5A yielded greatest
overall KD of CYP3A5 mRNA levels, as determined by qPCR (Figure 3-8A). The other
4 genes, upon deconvolution, only had one siRNA each that resulted in CYP3A5 levels
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Figure 3-6.

siRNA Screen Analysis

A. Example of InCell Analyzer masking. Yellow indicates CYP3A5 staining, green
indicates phallodin-488 staining, and blue indicates DAPI nuclei staining B. Waterfall
plot ranking siRNAs according to SSMD.

Figure 3-7.

Top 20 Screen Hit Confirmation

siRNA directed to each of the top 20 screen hits was reverse transfected into AsPC-1
cells for 72 hr at a final concentration of 25 nM. A-D. Western blots of the 20 hits for
CYP3A5 and β-actin antibodies. 40 µg protein loaded per well. E-F. qPCR showing fold
change (ddCt over GAPDH) for CYP3A5.
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Figure 3-8.

Top 5 Screen Hit siRNA Deconvolution

A-E. siNT5, siCYP3A5, and individual siRNA targeting the top 5 hits were reverse
transfected into AsPC-1 cells for 72 hr at a final concentration of 25 nM. CYP3A5 fold
change and gene-specific expression are shown for A. PHF5A, B. BARX2, C. ZNF354A,
D. CDX2, and E. SMARCD1.
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decreasing below 50% as compared to control siRNA (Figure 3-8B-E). A second
replicate of siPHF5A deconvolution was done to verify findings and to compare pooled
siRNA to individual. It was confirmed that all individual siRNA lead to CYP3A5 mRNA
decreases below 50%, with siPHF5A #2 and #18 mimicking the efficacy of the pooled
siRNA (Figure 3-9A). For each treatment, the PHF5A KD efficiency was excellent,
indicating good transfection efficiency and destruction of the target mRNA
(Figure 3-9B). A western blot was performed on these same samples, and there was a
corresponding decrease of CYP3A5 protein upon PHF5A KD for both pooled and
individual siRNA (Figure 3-9C).
This project subsequently centered on the top hit of interest, PHF5A, due to the
observed phenotype upon KD. It is unknown how siPHF5A leads to decreased CYP3A5
mRNA and protein levels. A time-course of PHF5A siRNA was performed to determine
optimal transfection conditions and to identify the window in which siPHF5A is
correlated with a maximal decrease in CYP3A5 levels. The timepoints were 24, 48, and
72 hours and it was found that siPHF5A had a time-dependent effect on CYP3A5 mRNA
levels (Figure 3-10A). PHF5A KD efficiency was similar in all timepoints
(Figure 3-10B). Confirmation of this phenotype was shown in AsPC-1 cells
(Figure 3-3A-C) and in 5 other PDAC lines via western blot (Figure 3-4A-D, lane 3)
and qPCR (Figure 3-4E-I).
The PAF1C as a Potential PHF5A Mechanism
After hit validation, the next step was to undertake mechanistic studies to
elucidate how the KD of PHF5A is related to the downregulation of CYP3A5. By
examining expression levels of CYP3A5 and PHF5A and experimental data, it was clear
that PHF5A and CYP3A5 basal levels do not correlate (Figure 3-2A-C). This indicates
that another protein or proteins may be involved. One published mechanism PHF5A
could be working through to affect CYP3A5 is the PAF1C. When using siRNA to knock
down individual members of the PAF1C, there is minimal or no effect on CYP3A5 levels
(Figure 3-11). Since the disruption of one complex member could potentially be
compensated for by the others. Double knock down samples addressed this issue and it
was found that when knocked down in combination, PAF1 and WDR61 seem to be
necessary for full CYP3A5 expression (Figure 3-11). Interestingly, CDC73 seems to
have a protective role by rescuing the decrease in CYP3A5 mRNA levels by KD of other
components of the PAF1C. Further studies may shed light on the intricacies of the
mechanism at play with the PAF1C/CYP3A5 relationship.
Splicing as a Potential PHF5A Mechanism
Another name for PHF5A is SF3b14b, named from its role as a member of the
SF3B subcomplex of the U2 snRNP of the spliceosome. Since CYP3A5 levels decrease
when PHF5A is knocked down, the next step was to manipulate key members of this
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Figure 3-9.

Deconvolution of siPHF5A in AsPC-1 Cells

A-C. siNT5, siCYP3A5, and pooled and individual siRNA targeting PHF5A were reverse
transfected into AsPC-1 cells for 72 hr at a final concentration of 25 nM. A-B. qPCR
showing fold change (ddCt over GAPDH) A. CYP3A5 expression. B. PHF5A KD
efficiency. C. Western blots for CYP3A5 and β-actin antibodies. 40 µg protein loaded per
well.
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Figure 3-10. siPHF5A Time Course
A-B. AsPC-1 cells were reverse transfected with siRNA targeting CYP3A5 and PHF5A,
with an siNT5 control, and cells were collected at 24, 48, and 72 hr post-transfection. A.
CYP3A5 fold change B. PHF5A KD efficiency.

Figure 3-11. siPAF1 and siWDR61 Affect CYP3A5 Expression
AsPC-1 cells were reverse transfected with siRNA targeting each of the 6 members of the
PAF1C, individually or in combination and collected 72 hr later for qPCR. Each siRNA
had a final concentration of 25 nM, therefore, in lanes 1-9, and equal proportion of siNT5
was supplemented to make the total siRNA concentration the same as double KD lanes.
A total of 50 nM siRNA was present in each well.

28

complex to assess their involvement and investigate if this is a PHF5A-specific effect. It
was found that knocking down SF3B1 and SF3B3 does lead to a corresponding decrease
in CYP3A5 protein (Figure 3-12A), but not mRNA (Figure 3-12B). Neither individual
or dual KD of these splicing factors decreased CYP3A5 levels to the extent that KD of
PHF5A did.
Using siRNA to target members of the spliceosome addresses the role of splicing
in CYP3A5 regulation from a genetic standpoint. Addressing this issue from a
pharmacological angle added confidence to this mechanistic study. Preliminary results
suggest that treating AsPC-1 cells with the splicing inhibitor Pladienolide B leads to
decreased levels of CYP3A5 (Figure 3-13A), mimicking the effect of PHF5A KD. A
proliferation assay established the standard growth curve in AsPC-1 for control treated
cells (Figure 3-13B). A range of Pladienolide B and Herboxidiene concentrations were
tested in AsPC-1 to determine toxic concentrations (Figure 3-13C-D). Initial findings
suggest that there are concentrations in which the drug is not toxic to the cells. These data
will need to be repeated and the drug-treated cells analyzed, as they were only carried out
once.
RNAseq Reveals siPHF5A Influence
To understand the scope of PHF5A influence in the AsPC-1 cell line, RNAseq of
siPHF5A vs siNT5 and lipid-only transfected cells was performed. qPCR was performed
before the samples were sent for sequencing to ensure good KD of PHF5A and CYP3A5
(Figure 3-14A). The sequencing core determined RIN values for each of the samples
before running the RNAseq as a quality control measure (Figure 3-14B). RIN is a metric
offered by the Agilent Bioanalyzer as an estimate of the extent of degradation of total
RNA. An ideal value is close to 10, and experimental values ranged from 9.6 to 10.
Briefly, the data produced by RNAseq of the siPHF5A samples produced two types of
data: splicing event data and gene expression data. A member of the bioinformatics core,
Dr. Finkelstein, performed MATS analysis to determine the number, frequency, and
identity of the alternative splicing events between the two data sets, siPHF5A vs siNT5
(Figure 3-14C). William C. Wright, did a thorough analysis of the differential gene
expression dataset. Preliminary conclusions are that PHF5A KD affects a host of other
genes besides CYP3A5, including MUC17 and GFAP (Figure 3-14D). Alternative
splicing can also be assessed with this dataset, and more detailed analysis is needed in
this area. Future validation and investigation will need to be undertaken to understand the
scope of PHF5A’s effect on drug metabolism, splicing, and other pathways in AsPC-1
cells.
Tools to Study PHF5A and CYP3A5
Thus far, siRNA has been employed to investigate the effects of knocking down
published and putative regulators of CYP3A5. Three stable cell lines were created from
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Figure 3-12. siSF3B Affects CYP3A5 Protein but Not mRNA
A-B. siNT5 and pooled siRNA targeting CYP3A5, PHF5A, SF3B1, and SF3B3 were
reverse transfected into AsPC-1 cells for 72 hr at a final concentration of 25 nM each, 50
nM total concentration as siNT5 was added to single KD samples to make the total
siRNA concentration equal. A. Western blot for CYP3A5, PHF5A, SF3B1, and β-actin
antibodies. 40 µg protein loaded per well. B. qPCR showing fold change (ddCt over
GAPDH) for CYP3A5.
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Figure 3-13. Splicing Inhibitors in AsPC-1 Cells
A. AsPC-1 cells were treated with Pladienolide B and a western was done with CYP3A5,
PHF5A, SF3B1, and β-actin antibodies. 40 µg protein loaded per well. B-D. AsPC-1
cells were seeded into 96-well plates, treated with compound and IncuCyte images were
taken every 6 hr for 96 hr. Time zero is time of drugging. Confluence was measured with
IncuCyte software. B. Growth curve of AsPC-1 cells in 0.1% DMSO. C. AsPC-1 cells
were treated with decreasing concentrations of Pladienolide B. D. AsPC-1 cells were
treated with decreasing concentrations of Herboxidiene.
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Figure 3-14. RNAseq Analysis of siPHF5A Samples
AsPC-1 cells were transfected with lipid only, siNT5, or siPHF5A pool and submitted in
triplicate for RNAseq analysis. A. RNAseq qPCR validation before submitting samples,
CYP3A5 fold change is shown. B. RIN mRNA degradation estimates for each RNAseq
sample. Generated by Dana Roeber. A1-C1 are lipid only, D1-F1 are siNT5, and G1-A2
are siPHF5A. C. Summary of the number and type of statistically significant alternative
splicing events, as determined by multivariate analysis of transcript splicing (MATS)
(false discovery rate <0.05). A3SS, alternative 3´ ends; A5SS, altered 5´ ends; SE,
cassette exons; and RI, retained introns. D. Gene expression volcano plot generated in
PRISM by William C. Wright.
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parental AsPC-1 cells to add a layer of confidence to this study and enable mechanistic
studies.
To provide better control of PXR expression/induction, a two-plasmid CRISPR
system was employed to knock out PXR in AsPC-1, the original pool displayed about a
50% decrease in PXR fold change (Figure 3-15A). Since this should be a KO, not a KD,
cells were expanded from single clones to identify clones which had KO of PXR
expression (Figure 3-15A).
An inducible KD system was used to generate inducible shPHF5A #2 to allow
temporal control over PHF5A KD. Cloning was done to insert the shPHF5A primers into
the pLKO parent plasmid. AsPC-1 cells were transduced and selected with puromycin to
isolate a population of stable cells that can be induced to KD PHF5A upon doxycycline
treatment. A doxycycline dose response was undertaken, and will need to be repeated as
it was performed only once. At all concentrations of doxycycline, PHF5A was knocked
down by about 40% and CYP3A5 accordingly decreased at some lower concentrations
(Figure 3-15B).
To study the effects of PHF5A KO in AsPC-1, four PHF5A-specific guide RNAs
(gRNAs) were transduced in AsPC-1 cells stably expressing Cas9. The cells containing
the two gRNAs that grew well after puromycin selection were expanded and collected for
downstream analysis. CYP3A5 levels were mildly decreased via qPCR (Figure 3-15C),
but not changes were detected via western blotting (Figure 3-15D).
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Figure 3-15. Tools Built for PHF5A Mechanistic Studies
PXR expression in PXR CRISPR KO AsPC-1 cell line. B. CYP3A5 and PHF5A
expression in tet-on-pLKO-puro shPHF5A AsPC-1 stable cells when induced with
decreasing concentration of doxycycline. C-D. PHF5A KO AsPC-1 cell line (pool). C.
CYP3A5 and PHF5A expression D. Western of CYP3A5, PHF5A, and β-actin
antibodies. 40 µg protein loaded per lane.
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CHAPTER 4.

DISCUSSION

The initial goal of this project was to investigate the regulation of CYP3A5 in a
pancreatic cancer cell line via an siRNA screen knocking down transcription factors and
chromatin-associated proteins, and to follow up on the regulatory mechanism of top hit
PHF5A. This led to initial probing into different potential mechanisms by which PHF5A
could be acting on CYP3A5. These studies were initiated in the AsPC-1 PDAC cell line
because of its high basal expression of CYP3A5 that can be knocked down with siRNA at
both the mRNA and the protein level (Figure 3-5A-B). Many of the mechanistic studies
will need to be repeated and expanded, but initial findings are promising, pointing to
PHF5A’s role in splicing.
Three stable cell lines were created in order to assist future work on this project
(Figure 3-15A-D). These include a PXR KO AsPC-1 cell line, a doxycycline-inducible
shPHF5A AsPC-1 cell line, and a PHF5A KO AsPC-1 line. These tools can approach the
question of CYP3A5 regulation by offering knocked out regulators and temporal control
of PHF5A KD. To determine if both alleles were affected by the CRISPR KO, PCR
amplification and sequencing of the gene will need to be done.
This project also brought to light the need to better understand CYP3A5 genotype
and the role this plays. The fact that homozygous CYP3A5*3 individuals express some
active CYP3A5 (Kuehl, 2001) indicates that CYP3A5*3 is a leaky allele. This is
supported by the data that shows full length CYP3A5 is detected in all CYP3A5expressing cell lines (Figure 3-1). Understanding how the CYP3A5*3 allele is generated
could lead to the ability to correct this genotype to alter phenotype, which could lead to
drug-sensitized cancers. The rs776746 SNP creates a cryptic acceptor splice site that
promotes the insertion pseudoexon 3B in the mature mRNA. This improperly spliced
mRNA contains a premature stop codon, preventing full length CYP3A5 protein from
being made. Remember, CYP3A5*3 homozygous individuals produce some active
CYP3A5, reinforcing that the splicing machinery has a choice of acceptor sites (Lee,
2007). The SNP occurs over 100 base pairs upstream from the splice donor site of exon 4,
and currently there are no models to explain how normal splicing is impaired but not
inhibited (Annalora, 2017). More in-depth studies need to be done to characterize this site
selection.
To answer the outstanding questions of this project, future work can be done
using isoform-specific probes to determine which isoform(s) of CYP3A5 are expressed in
each cell line, which are affected by siPHF5A, and how this affects drug metabolism.
All 8 PDAC lines in this study have the same genotype, but PANC-1 and MIA
PaCa-1 are not abundant in CYP3A5 mRNA or protein (Figure 3-1A,C). So, what makes
the expression profile different? Differential regulation? Co-occurring mutations? Not
only is this an interesting basic biological question, it is also applicable in
pharmacogenomics. Understanding a patient’s CYP SNP panel would further the field
of personalized medicine and improved therapeutics.

35

LIST OF REFERENCES
Annalora AJ, Marcus CB and Iversen PL (2017) Alternative Splicing in the Cytochrome
P450 Superfamily Expands Protein Diversity to Augment Gene Function and
Redirect Human Drug Metabolism. Drug Metab Dispos 45:375-389. doi:
10.1124/dmd.116.073254
Basseville A, Preisser L, de Carne Trecesson S, Boisdron-Celle M, Gamelin E, Coqueret
O and Morel A (2011) Irinotecan induces steroid and xenobiotic receptor (SXR)
signaling to detoxification pathway in colon cancer cells. Mol Cancer 10:80. doi:
10.1186/1476-4598-10-80
Bolbrinker J, Seeberg S, Schostak M, Kempkensteffen C, Baelde H, de Heer E and
Kreutz R (2012) CYP3A5 genotype-phenotype analysis in the human kidney
reveals a strong site-specific expression of CYP3A5 in the proximal tubule in
carriers of the CYP3A5*1 allele. Drug Metab Dispos 40:639-41. doi:
10.1124/dmd.111.042648
Burk O, Koch I, Raucy J, Hustert E, Eichelbaum M, Brockmoller J, Zanger UM and
Wojnowski L (2004) The induction of cytochrome P450 3A5 (CYP3A5) in the
human liver and intestine is mediated by the xenobiotic sensors pregnane X
receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem
279:38379-85. doi: 10.1074/jbc.M404949200
Conrad T, Albrecht AS, de Melo Costa VR, Sauer S, Meierhofer D and Orom UA (2016)
Serial interactome capture of the human cell nucleus. Nat Commun 7:11212. doi:
10.1038/ncomms11212
Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, Shen DD and Thummel KE
(2006) Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in
vitro. Drug Metab Dispos 34:836-47. doi: 10.1124/dmd.105.008680
Dorr CR, Remmel RP, Muthusamy A, Fisher J, Moriarity BS, Yasuda K, Wu B, Guan W,
Schuetz EG, Oetting WS, Jacobson PA and Israni AK (2017) CRISPR/Cas9
Genetic Modification of CYP3A5 *3 in HuH-7 Human Hepatocyte Cell Line
Leads to Cell Lines with Increased Midazolam and Tacrolimus Metabolism. Drug
Metab Dispos 45:957-965. doi: 10.1124/dmd.117.076307
Downie D, McFadyen MC, Rooney PH, Cruickshank ME, Parkin DE, Miller ID, Telfer
C, Melvin WT and Murray GI (2005) Profiling cytochrome P450 expression in
ovarian cancer: identification of prognostic markers. Clin Cancer Res 11:7369-75.
doi: 10.1158/1078-0432.ccr-05-0466
Effenberger KA, Urabe VK and Jurica MS (2017) Modulating splicing with small
molecular inhibitors of the spliceosome. Wiley Interdiscip Rev RNA 8. doi:
10.1002/wrna.1381
Falck E and Klinga-Levan K (2013) Expression patterns of Phf5a/PHF5A and
Gja1/GJA1 in rat and human endometrial cancer. Cancer Cell Int 13:43. doi:
10.1186/1475-2867-13-43
Huang W, Lin YS, McConn DJ, 2nd, Calamia JC, Totah RA, Isoherranen N, Glodowski
M and Thummel KE (2004) Evidence of significant contribution from CYP3A5
to hepatic drug metabolism. Drug Metab Dispos 32:1434-45. doi:
10.1124/dmd.104.001313

36

Hukkanen J, Vaisanen T, Lassila A, Piipari R, Anttila S, Pelkonen O, Raunio H and
Hakkola J (2003) Regulation of CYP3A5 by glucocorticoids and cigarette smoke
in human lung-derived cells. J Pharmacol Exp Ther 304:745-52. doi:
10.1124/jpet.102.038208
Iyanagi T (2007) Molecular mechanism of phase I and phase II drug-metabolizing
enzymes: implications for detoxification. Int Rev Cytol 260:35-112. doi:
10.1016/s0074-7696(06)60002-8
Jover R, Bort R, Gomez-Lechon MJ and Castell JV (2001) Cytochrome P450 regulation
by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirusmediated antisense targeting. Hepatology 33:668-75. doi:
10.1053/jhep.2001.22176
Kashyap MK, Kumar D, Villa R, La Clair JJ, Benner C, Sasik R, Jones H, Ghia EM,
Rassenti LZ, Kipps TJ, Burkart MD and Castro JE (2015) Targeting the
spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and
pladienolide-B. Haematologica 100:945-54. doi: 10.3324/haematol.2014.122069
Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, Nuessler A, Neuhaus P,
Eichelbaum M, Zanger U and Wojnowski L (2002) Interindividual variability and
tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab
Dispos 30:1108-14
Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton
SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R,
Strom S, Thummel K, Boguski MS and Schuetz E (2001) Sequence diversity in
CYP3A promoters and characterization of the genetic basis of polymorphic
CYP3A5 expression. Nat Genet 27:383-91. doi: 10.1038/86882
Kumarakulasingham M, Rooney PH, Dundas SR, Telfer C, Melvin WT, Curran S and
Murray GI (2005) Cytochrome p450 profile of colorectal cancer: identification of
markers of prognosis. Clin Cancer Res 11:3758-65. doi: 10.1158/1078-0432.ccr04-1848
Lee SJ, van der Heiden IP, Goldstein JA and van Schaik RH (2007) A new CYP3A5
variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a
recombinant cDNA expression system. Drug Metab Dispos 35:67-71. doi:
10.1124/dmd.106.012310
Lodish H, Berk A, Zipursky SL, et al. Molecular Cell Biology. 4th edition. New York:
W. H. Freeman; 2000. Section 11.2, Processing of Eukaryotic mRNA. Available
from: https://www.ncbi.nlm.nih.gov/books/NBK21563/
Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, Zhou X, Li Y, Rusch
MC, Easton J, Huether R, Gonzalez-Pena V, Wilkinson MR, Hermida LC, Davis
S, Sioson E, Pounds S, Cao X, Ries RE, Wang Z, Chen X, Dong L, Diskin SJ,
Smith MA, Guidry Auvil JM, Meltzer PS, Lau CC, Perlman EJ, Maris JM,
Meshinchi S, Hunger SP, Gerhard DS and Zhang J (2018) Pan-cancer genome
and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours.
Nature 555:371-376. doi: 10.1038/nature25795
Maguire O, Pollock C, Martin P, Owen A, Smyth T, Doherty D, Campbell MJ, McClean
S and Thompson P (2012) Regulation of CYP3A4 and CYP3A5 expression and
modulation of "intracrine" metabolism of androgens in prostate cells by liganded

37

vitamin D receptor. Mol Cell Endocrinol 364:54-64. doi:
10.1016/j.mce.2012.08.007
Martinez-Montiel N, Rosas-Murrieta NH, Martinez-Montiel M, Gaspariano-Cholula MP
and Martinez-Contreras RD (2016) Microbial and Natural Metabolites That
Inhibit Splicing: A Powerful Alternative for Cancer Treatment. Biomed Res Int
2016:3681094. doi: 10.1155/2016/3681094
Nebert DW, Wikvall K and Miller WL (2013) Human cytochromes P450 in health and
disease. Philos Trans R Soc Lond B Biol Sci 368:20120431. doi:
10.1098/rstb.2012.0431
Nelson DR (2009) The cytochrome p450 homepage. Hum Genomics 4:59-65.
Noll EM, Eisen C, Stenzinger A, Espinet E, Muckenhuber A, Klein C, Vogel V, Klaus B,
Nadler W, Rosli C, Lutz C, Kulke M, Engelhardt J, Zickgraf FM, Espinosa O,
Schlesner M, Jiang X, Kopp-Schneider A, Neuhaus P, Bahra M, Sinn BV, Eils R,
Giese NA, Hackert T, Strobel O, Werner J, Buchler MW, Weichert W, Trumpp A
and Sprick MR (2016) CYP3A5 mediates basal and acquired therapy resistance in
different subtypes of pancreatic ductal adenocarcinoma. Nat Med 22:278-87. doi:
10.1038/nm.4038
Ohtsuki S, Schaefer O, Kawakami H, Inoue T, Liehner S, Saito A, Ishiguro N, Kishimoto
W, Ludwig-Schwellinger E, Ebner T and Terasaki T (2012) Simultaneous
absolute protein quantification of transporters, cytochromes P450, and UDPglucuronosyltransferases as a novel approach for the characterization of
individual human liver: comparison with mRNA levels and activities. Drug Metab
Dispos 40:83-92. doi: 10.1124/dmd.111.042259
Oltra E, Pfeifer I and Werner R (2003) Ini, a small nuclear protein that enhances the
response of the connexin43 gene to estrogen. Endocrinology 144:3148-58. doi:
10.1210/en.2002-0176
Raunio H, Hakkola J and Pelkonen O (2005) Regulation of CYP3A genes in the human
respiratory tract. Chem Biol Interact 151:53-62. doi: 10.1016/j.cbi.2003.12.007
Rouillard AD, Gundersen GW, Fernandez NF, Wang Z, Monteiro CD, McDermott MG
and Ma'ayan A (2016) The harmonizome: a collection of processed datasets
gathered to serve and mine knowledge about genes and proteins. Database
(Oxford) 2016. doi: 10.1093/database/baw100
Rzymski T, Grzmil P, Meinhardt A, Wolf S and Burfeind P (2008) PHF5A represents a
bridge protein between splicing proteins and ATP-dependent helicases and is
differentially expressed during mouse spermatogenesis. Cytogenet Genome Res
121:232-44. doi: 10.1159/000138890
Saeki M, Saito Y, Nakamura T, Murayama N, Kim SR, Ozawa S, Komamura K, Ueno K,
Kamakura S, Nakajima T, Saito H, Kitamura Y, Kamatani N and Sawada J (2003)
Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a
Japanese population. Hum Mutat 21:653. doi: 10.1002/humu.9147
Strikoudis A, Lazaris C, Ntziachristos P, Tsirigos A and Aifantis I (2017) Opposing
functions of H2BK120 ubiquitylation and H3K79 methylation in the regulation of
pluripotency by the Paf1 complex. Cell Cycle 16:2315-2322. doi:
10.1080/15384101.2017.1295194

38

Vaz AP, Ponnusamy MP, Rachagani S, Dey P, Ganti AK and Batra SK (2014) Novel role
of pancreatic differentiation 2 in facilitating self-renewal and drug resistance of
pancreatic cancer stem cells. Br J Cancer 111:486-96. doi: 10.1038/bjc.2014.152
Wee S, Wiederschain D, Maira SM, Loo A, Miller C, deBeaumont R, Stegmeier F, Yao
YM and Lengauer C (2008) PTEN-deficient cancers depend on PIK3CB. Proc
Natl Acad Sci U S A 105:13057-62. doi: 10.1073/pnas.0802655105
Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I,
Edwards RJ, Boobis AR and Ingelman-Sundberg M (2003) Comparative analysis
of CYP3A expression in human liver suggests only a minor role for CYP3A5 in
drug metabolism. Drug Metab Dispos 31:755-61.
Wiederschain D, Wee S, Chen L, Loo A, Yang G, Huang A, Chen Y, Caponigro G, Yao
YM, Lengauer C, Sellers WR and Benson JD (2009) Single-vector inducible
lentiviral RNAi system for oncology target validation. Cell Cycle 8:498-504. doi:
10.4161/cc.8.3.7701
Will CL, Urlaub H, Achsel T, Gentzel M, Wilm M and Luhrmann R (2002)
Characterization of novel SF3b and 17S U2 snRNP proteins, including a human
Prp5p homologue and an SF3b DEAD-box protein. EMBO J 21:4978-88.
Zanger UM and Schwab M (2013) Cytochrome P450 enzymes in drug metabolism:
regulation of gene expression, enzyme activities, and impact of genetic variation.
Pharmacol Ther 138:103-41. doi: 10.1016/j.pharmthera.2012.12.007
Start the first entry on this line at the left margin, leaving no space or 1 space between the
single-spaced entries that are left justified with a hanging indent (as here).

39

VITA
Jessica DeeAnn Hoyer, daughter of Mark and Candy Maddox, was born in 1991
in Houston, Texas. Upon completing her B.S. in Molecular and Cellular Biology at
Harding University in Searcy, Arkansas, she began graduate school at the University of
Tennessee Health Science Center in Memphis, Tennessee. After meeting all
requirements, including approval of this manuscript, she will receive a Master of Science
degree in Biomedical Sciences with a concentration in Cancer and Developmental
Biology in June 2019.

40

